Forecast

The analysts' average price target is €31.24 (+149.92%). The median is €31.07 (+148.56%).

Buy	14
Hold	21
Sell	1

News Go to news feed

Perrigo unveils realignment and targets €80–100 million in cost savings

At the Canaccord growth conference Perrigo presented a 3‑S plan (stabilize, simplify, strengthen) to accelerate its turnaround, including portfolio simplification and a focus on category-led innovation. Management expects annual savings of €80–100 million, about 80% of which are planned for 2026, and a rebound in demand in the second half of 2026. E‑commerce is growing significantly faster than brick-and-mortar retail and should drive market share gains; strategic reviews cover infant nutrition and oral care, and disposals to reduce debt are possible. Perrigo stresses that implementing the measures and improving trade relationships with partners such as Walmart, Dollar General and Amazon should lay the foundation for long-term growth. » More on de.investing.com
Perrigo stock jumps 24% after surprise Q2 EPS beat

Perrigo reported adjusted diluted EPS of $0.50 for Q2 2026 (consensus $0.34) and adjusted core EPS of $0.46 on revenue of about $1.02 billion, sending the stock up roughly 24%. The unexpectedly strong result was attributed to aggressive cost cuts and operational discipline under the “Three‑S” strategy, although core net sales declined about 3.1%. The sale of the dermocosmetics unit generated approximately €305.6 million and will be used to reduce debt; management reiterated full‑year guidance of adjusted total EPS of $2.00–$2.30 and adjusted core EPS of $2.25–$2.55. » More on de.investing.com
Perrigo approves quarterly dividend of $0.29

Perrigo's board of directors has approved a quarterly dividend of $0.29 per share, payable on September 15, 2026 to shareholders of record on August 28, 2026. On an annual basis this corresponds to $1.16 per share. Perrigo markets over-the-counter self-medication products primarily in North America and Europe. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Perrigo Company has already paid €0.50 in dividends. The last payout was in June.

Financials

In the last quarter, Perrigo Company had revenue of €897.72M and net profit of €65.39M

(EUR)	Jun 2026	YoY
Revenue	897.72M	0.40%
Gross profit	275.51M	11.03%
Net profit	65.39M	1,012.27%
EBITDA	126.21M	14.57%

Fundamentals

Metric	Value
Market capitalization	€1.73B
Number of shares	138.37M
52-week high/low	€20.67 - €7.97
Dividend yield	7.94%
Dividends TTM	€0.99
Next dividend	€0.25
Beta	0.54
P/E ratio	-1.16
PEG ratio	0.00
P/B ratio	0.80
P/S ratio	0.48

Company profile

Perrigo Company plc bietet rezeptfreie Gesundheits- und Wellnesslösungen an, die das individuelle Wohlbefinden steigern, indem sie den Verbrauchern die Möglichkeit geben, Krankheiten vorzubeugen oder zu behandeln, die sie selbst behandeln können. Das Unternehmen ist in zwei Segmenten tätig: Consumer Self-Care Americas und Consumer Self-Care International. Das Segment Consumer Self-Care Americas konzentriert sich in erster Linie auf die Entwicklung, Herstellung, Vermarktung und den Verkauf von Eigenmarkenprodukten zur Selbstversorgung in Kategorien wie obere Atemwege, Schmerz- und Schlafmittel, Verdauungsgesundheit, Ernährung, Vitamine, Mineralien und Nahrungsergänzungsmittel, gesunder Lebensstil, Hautpflege und Körperpflege sowie orale Selbstversorgung in den Vereinigten Staaten, Mexiko, Kanada und Südamerika. Das Segment bietet seine Produkte unter den Markennamen Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh und Burt's Bees an. Das Segment Consumer Self-Care International entwickelt, produziert, vermarktet und vertreibt Marken für die Selbstpflege von Verbrauchern über ein Netzwerk von Apotheken, Großhändlern, Drogerie- und Lebensmitteleinzelhändlern sowie Parapharmazien in etwa 23 Ländern, hauptsächlich in Europa. Das Unternehmen bietet auch Dienstleistungen im Bereich der Auftragsherstellung an. Die Perrigo Company plc wurde 1887 gegründet und hat ihren Hauptsitz in Dublin, Irland.